Xeris Q2 ’18 10-Q Filing Highlights

Xeris Pharmaceuticals filed its first 10-Q statement since its IPO in June 2018. In the 10-Q, Xeris confirmed filing of its Glucagon Rescue Pen in Q3 ‘18 via the 505(b)(2) pathway. Yesterday, Xeris released its Q2 ’18 earnings but did not have an associated earnings webcast.

About The Author

Matthew Maryniak

President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.